Literature DB >> 19046193

Fasting plasma glucose and HbA1c as risk factors for Type 2 diabetes.

Kazuo Inoue1, Masatoshi Matsumoto, Kimihiko Akimoto.   

Abstract

AIMS: We examined the value of combining fasting plasma glucose (FPG) and glycated haemoglobin (HbA(1c)) as a predictor of diabetes, using the new American Diabetes Association (ADA) criteria of FPG and lower cut-off point of HbA(1c).
METHODS: A retrospective cohort study was conducted from 1998 to 2006, inclusive, in 10 042 persons (55 884 person-years), with a mean age of 53.0 years at baseline. The cumulative incidence of diabetes (defined either as an FPG > or = 7.0 mmol/l or as clinically diagnosed diabetes) was measured.
RESULTS: The cumulative incidence and incidence density of diabetes were 3.7% (368 cases) and 6.6/1000 person-years over a mean follow-up period of 5.5 years. The cumulative incidence of diabetes in subjects with impaired fasting glucose (IFG) and HbA(1c) 5.5-6.4% was 24.8% (172/694 persons) compared with 0.4% (25/6698 persons), 2.5% (15/605 persons), 7.6% (156/2045 persons) in those with normal fasting glucose (NFG) and HbA(1c) < 5.5%, NFG and HbA(1c) 5.5-6.4% and IFG and HbA(1c) < 5.5%, respectively. The hazard ratio for diabetes, adjusted for possible confounders, was 7.4 (95% confidence interval, 4.70 to 11.74) for those with NFG and HbA(1c) 5.5-6.4%, 14.4 (11.93 to 27.79) for those with IFG and HbA(1c) < 5.5% and 38.4 (24.63 to 59.88) for those with IFG and HbA(1c) 5.5-6.4%.
CONCLUSIONS: The combination of FPG and HbA(1c) identifies individuals who are at risk of progression to Type 2 diabetes at the new ADA criteria of FPG and a lower cut-off point of HbA(1c) than previous studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19046193     DOI: 10.1111/j.1464-5491.2008.02572.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  21 in total

1.  Glycated hemoglobin in diagnosis of diabetes mellitus and pre-diabetes; validation by oral glucose tolerance test. The Tromsø OGTT Study.

Authors:  M S Hutchinson; R M Joakimsen; I Njølstad; H Schirmer; Y Figenschau; R Jorde
Journal:  J Endocrinol Invest       Date:  2011-12-16       Impact factor: 4.256

2.  Does vertebral bone marrow fat content correlate with abdominal adipose tissue, lumbar spine bone mineral density, and blood biomarkers in women with type 2 diabetes mellitus?

Authors:  Thomas Baum; Samuel P Yap; Dimitrios C Karampinos; Lorenzo Nardo; Daniel Kuo; Andrew J Burghardt; Umesh B Masharani; Ann V Schwartz; Xiaojuan Li; Thomas M Link
Journal:  J Magn Reson Imaging       Date:  2011-08-16       Impact factor: 4.813

3.  Impaired glucose tolerance in sleep disorders.

Authors:  Marietta Keckeis; Zuzana Lattova; Eszter Maurovich-Horvat; Pierre A Beitinger; Steffen Birkmann; Christoph J Lauer; Thomas C Wetter; Johanna Wilde-Frenz; Thomas Pollmächer
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

4.  A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS).

Authors:  Carlos Lorenzo; Lynne E Wagenknecht; Anthony J G Hanley; Marian J Rewers; Andrew J Karter; Steven M Haffner
Journal:  Diabetes Care       Date:  2010-06-23       Impact factor: 19.112

5.  Comparison of fasting glucose with post-load glucose values and glycated hemoglobin for prediction of type 2 diabetes: the Isfahan diabetes prevention study.

Authors:  Mohsen Janghorbani; Masoud Amini
Journal:  Rev Diabet Stud       Date:  2009-08-10

6.  Examination of the Allostatic Load Construct and Its Longitudinal Association With Health Outcomes in the Boston Puerto Rican Health Study.

Authors:  Andrea López-Cepero; Amanda C McClain; Milagros C Rosal; Katherine L Tucker; Josiemer Mattei
Journal:  Psychosom Med       Date:  2022-01-01       Impact factor: 4.312

7.  Glycated hemoglobin and risk of hypertension in the atherosclerosis risk in communities study.

Authors:  Julie K Bower; Lawrence J Appel; Kunihiro Matsushita; J Hunter Young; Alvaro Alonso; Frederick L Brancati; Elizabeth Selvin
Journal:  Diabetes Care       Date:  2012-03-19       Impact factor: 19.112

8.  Concordance of two diabetes diagnostic criteria using fasting plasma glucose and hemoglobin A1c: the Yuport Medical Checkup Centre study.

Authors:  Kazuo Inoue; Saori Kashima; Chisako Ohara; Masatoshi Matsumoto; Kimihiko Akimoto
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

9.  Usefulness of glycated hemoglobin as diagnostic criteria for metabolic syndrome.

Authors:  Sang Hyun Park; Ji Sung Yoon; Kyu Chang Won; Hyoung Woo Lee
Journal:  J Korean Med Sci       Date:  2012-08-22       Impact factor: 2.153

10.  Do non-glycaemic markers add value to plasma glucose and hemoglobin a1c in predicting diabetes? Yuport health checkup center study.

Authors:  Saori Kashima; Kazuo Inoue; Masatoshi Matsumoto; Kimihiko Akimoto
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.